

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NOVARTIS CORP

2. Address:

701 PENNSYLVANIA AVE NW #725, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: ANDREA MCCABE

Telephone: 202-638-7429

E-mail (optional): andrea.mccabe@group.novartis.com

Senate ID #: 9204-12

House ID #: 33589000

7. Client Name: Self

TYPE OF REPORT

8. Year 2005 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: Dec 30, 1899 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 1,841,931.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R.2218 Regulation of non corrective contact lens as medical devices S.930 Food and Drug Administration Safety Act of 2005
H.R.2090 Food and Drug Administration Improvement Act of 2005 H.R.3196 - Fair Access to Clinical Trials Act S. 470 - FACT Act
H.R.3428 - OTC Medicine Tax Fairness Act of 2005 S.1514 - OTC Medicine Tax Fairness Act of 2005 S.172 - To amend the Federal
Food, Drug, and Cosmetic Act to provide for the regulation of all contact lenses as medical devices, and for other purposes. H.R.371 -
To amend the Federal Food, Drug, and Cosmetic Act to provide for the regulation of all contact lenses as medical devices, and for other
purposes. S.103 - Combat Meth Act of 2005 H.R.314 - Combat Meth Act of 2005 S.950 Elimination of Neglected Diseases Act of
2005 H.R.3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006 Drug Importation Medicare Part
B and Part D Sickle Cell Anemia Immunosuppressant Legislation Cancer Therapies Legislation Gene Therapy Direct to Consumer
Advertising Medicare Prescription Drugs & Modernization Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH

Covered Official Position (if applicable): DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: CASSERLY, DAN

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: DRAKE, DAVID

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: ELKIN, JAMES

Covered Official Position (if applicable): VICE PRESIDENT, FEDERAL GOVERNMENT RELATIONS

Name: GILES, THOMAS

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS

Name: HALLER, SARAH

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, INTERNATIONAL AND PUBLIC AFFAIRS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS CORP Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

China/World Trade Organization Free Trade Agreements

17. House(s) of Congress and Federal agencies contacted:
U.S. Agency for International Development (USAID)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: HALLER, SARAH

Covered Official Position (if applicable): EXECUTIVE DIRECTOR, INTERNATIONAL AND PUBLIC AFFAIRS

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree tht public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature: ON FILE Date: Aug 09, 2005

Printed Name and Title: DAN CASSERLY - EXECUTIVE DIRECTOR, FEDERAL GOVERNMENT RELATIONS